Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Disseminated cutaneous Herpes Simplex Virus-1 in a woman with rheumatoid arthritis receiving Infliximab: A case report | Journal of Medical Case Reports BioMed Central Open Access Case report Disseminated cutaneous Herpes Simplex Virus-1 in a woman with rheumatoid arthritis receiving Infliximab A case report Elizabeth Ann Justice Sophia Yasmin Khan Sarah Logan and Paresh Jobanputra Address Rheumatology Department Selly Oak Hospital University Hospital Birmingham NHS Trust Raddlebarn Road Birmingham B29 6JD UK Email Elizabeth Ann Justice - elizabethjustice@yahoo.com Sophia Yasmin Khan - sophiagoble@btinternet.com Sarah Logan - sarah.logan@uhb.nhs.uk Paresh Jobanputra - paresh.jobanputra@uhb.nhs.uk Corresponding author Published 26 August 2008 Received 7 November 2007 Journal of Medical Case Reports 2008 2 282 doi 10.1186 1752-1947-2-282 Accepted 26 August 2008 This article is available from http www.jmedicalcasereports.cOm content 2 1 282 2008 Ann Justice et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction We present the case of a 49-year-old woman with a seronegative rheumatoid arthritis who developed pustular psoriasis whilst on etanercept and subsequently developed disseminated herpes simplex on infliximab. Case presentation Our patient presented with an inflammatory arthritis which failed to respond to both methotrexate and leflunomide and sulphasalazine treatment led to side effects. She was started on etanercept but after 8 months of treatment developed scaly pustular lesions on her palms and soles typical of pustular psoriasis. Following the discontinuation of etanercept our patient required high doses of oral prednisolone to control her inflammatory arthritis. A second biologic agent infliximab was introduced in addition to low-dose methotrexate and 15 mg of oral prednisolone. However after just 3 infusions of .
